Clinical Outcomes of Patients with High-risk Metastatic Hormone-naïve Prostate Cancer: A 3-year Interim Analysis of the Observational J-ROCK Study-Reference-Cited by-同舟云学术

Clinical Outcomes of Patients with High-risk Metastatic Hormone-naïve Prostate Cancer: A 3-year Interim Analysis of the Observational J-ROCK Study

Published:2024-06 Issue:3 Volume:7 Page:625-632
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Miyake Hideaki,Matsumoto Rikiya,Fujimoto Kiyohide,Mizokami Atsushi,Uemura Hirotsugu,Kamoto Toshiyuki,Kawakami Satoru,Nakamura Kazuyoshi,Maekawa Shigekatsu,Shibayama Kazuhiro,Watanabe Aki,Ito Miku,Tajima Yohei,Matsuyama Hideyasu,Uemura Hiroji

Funder

Janssen Pharmaceutical KK

Publisher

Elsevier BV

Reference26 articles.

1. Recent trends in the initial therapy for newly diagnosed prostate cancer in Japan;Onozawa;Jpn J Clin Oncol,2014

2. A new old target: androgen receptor signaling and advanced prostate cancer;Westaby;Annu Rev Pharmacol Toxicol,2022

3. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naïve prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study;Fukasawa;Jpn J Clin Oncol,2018

4. Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: a subgroup analysis of the phase III ARCHES study;Iguchi;Int J Urol,2021

5. Safety and efficacy of apalutamide in Japanese patients with metastatic castration‐sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo‐controlled, phase III TITAN study

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A novel prognostic model of de novo metastatic hormone-sensitive prostate cancer to optimize treatment intensity;International Journal of Clinical Oncology;2024-07-19

2. Changes in the treatment landscape of metastatic hormone‐sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter study;International Journal of Urology;2024-07-19

3. Comparison of oncological outcomes of upfront androgen receptor signaling inhibitors and combined androgen blockade in Japanese patients with metastatic castration-sensitive prostate cancer;Global Health & Medicine;2024-06-30